Abstract P2-08-08: A population-based study examining the epidemiology, treatment patterns and resource utilization by stage in Ontario patients with triple negative breast cancer
Notice bibliographique
Résumé
Abstract Background: There is limited current data on the incidence, clinical characteristics, treatment patterns, and resource utilization in breast cancer patients with a triple negative (TNBC) clinical phenotype (ER-/PR-/HER2-). Moreover, no prior publications have detailed the differences in resource use according to TNBC stage in a publicly funded healthcare setting. Methods: We retrospectively collected data for women aged 18-105 years, residing in Ontario, utilizing the public healthcare system, and diagnosed with invasive BC from Apr 1, 2012 to Mar 31, 2016. Data were extracted from datasets housed by the Institute for Clinical Evaluative Sciences. Women with triple negative pathology were identified and baseline clinical characteristics, treatment patterns, and healthcare resource utilization were descriptively compared between stage I-III and stage IV sub-cohorts. Outcomes assessed included 5-year overall survival (OS) rate by stage. Patients alive/lost to follow-up at the end of the study period (Mar 31, 2017) were censored. Unit costs (2017 CAD $) for publicly funded healthcare services were multiplied by resources used in order to calculate the total and annual health system-related costs. Results: In total, 3,271 women were identified as having TNBC; 3,081 with stage I-III and 190 with stage IV disease at diagnosis. Patients with metastatic TNBC tended to be older (63.9 ± 15.7 years) compared to those with stage I-III disease (58.8 ± 14.4 years). With a median follow-up of 34.5, 32.7, 26.2 and 8.9 mos, 5-year OS rates were 93.3%, 78.9%, 47.2% and 7.4% for stage I, II, III, and IV, respectively. Surgery was the most common treatment modality among patients with stage I-III (n=2,979, 96.7%) and least common in those with stage IV (n=16, 8.4%) disease. Among patients treated with upfront surgery for early stage disease (n=2,419, 81.2%), 1,890 (78.1%) received adjuvant systemic therapy (AT) with a median time from surgery to treatment of 45 days (IQR: 35,62). The remaining 560 patients (18.8%) with stage I-III disease received neo-AT starting a median of 28 days (IQR: 21,39) after diagnosis, with 221 (39.5%) also receiving AT. In total, 2,341 (76.0%) of patients with stage I-III BC received radiation. Among patients with metastatic TNBC, 138 (72.6%) received systemic therapy and 109 (57.4%) were treated with radiotherapy. Annual mean healthcare cost per person was $35,063.96 for stage I-III and $140,160.23 for stage IV TNBC. In both early and metastatic TNBC, cancer clinic visits, in-patient hospitalization, and professional fees were the main contributors to healthcare costs whereas pharmaceutical, home care, day surgery and continuing care contributed <10% each to the total annual expenses. Conclusions: Characteristics and clinical outcomes were as expected for our Ontario-based population of women with TNBC. Our data highlights room for improvement related to wait times for surgery and initiation of systemic therapy in patients with early stage TNBC; an important endeavour considering the aggressiveness of this disease. Despite receiving fewer treatment interventions (surgery, pharmacologic and/or radiation), patients with stage IV TNBC incurred more healthcare costs per person than those with earlier stage disease. These data illustrate the treatment patterns and resource utilization for women with TNBC in Ontario and highlight opportunities to improve their outcomes. Citation Format: Christine Brezden-Masley, Kelly Elizabeth Fathers, Megan Coombes, Cloris Xue, Behin Pourmirza, Katarzyna J. Jerzak. A population-based study examining the epidemiology, treatment patterns and resource utilization by stage in Ontario patients with triple negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-08.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».